Open for inclusion

The Melanoma Goup Trial: TOL + vemurafenib followed by interferon + vemurafenib maintenance (BRAF-positive patients) or TOL followed by interferon maintenance (BRAF-negative patients)

Cancer type: Melanoma

Phase: II

Principal Investigator: Hernberg Micaela

Country: FI

Keywords: Finland

Status: Inclusion completed